[{"id":"6705e7e6-5f76-403e-847f-2fbe43967ddb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241106","created_at":"2022-02-15T15:52:44.070Z","updated_at":"2024-07-02T16:35:03.973Z","phase":"Phase 2","brief_title":"A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241106","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-14"},{"id":"f65efc53-8b60-4d72-9e77-531f3964de27","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241093","created_at":"2022-02-15T15:52:43.789Z","updated_at":"2024-07-02T16:35:03.939Z","phase":"Phase 2","brief_title":"A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241093","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-14"}]